Emzor Raises $20 Million Bond to Expand Local Drug Manufacturing in Nigeria 🇳🇬

Emzor Raises $20 Million Bond to Expand Local Drug Manufacturing in Nigeria 🇳🇬

Nigerian pharmaceutical company Emzor Pharmaceutical Industries is turning to the local debt market to finance its next phase of growth, raising $20 million (about ₦26.7 billion) through a five-year bond.The bond, issued by Emzor Pharma Funding SPV Plc, carries a 19% interest rate* and forms part of the company’s broader ₦40 billion debt programme. The funds are expected to support working capital, expand manufacturing capacity and help complete what is described as Africa’s first full-scale antimalarial Active Pharmaceutical Ingredient (API) plant.The transaction is significant not only for Emzor, but also for Nigeria’s efforts to strengthen domestic pharmaceutical manufacturing.

## From a Lagos chemist shop to a major drug manufacturerEmzor’s story goes back to 1977, when the company was founded by Nigerian pharmacist Stella Okoli.

What started as a small chemist shop in Lagos has grown into one of Nigeria’s major pharmaceutical manufacturers, with a portfolio of more than 120 medicines spanning 16 therapeutic categories.The company’s latest fundraising signals a shift from simply manufacturing medicines locally to building more of the infrastructure required to produce pharmaceutical inputs within the country.That distinction matters.

Nigeria remains heavily dependent on imported pharmaceutical ingredients and finished products. When global supply chains are disrupted, currency pressures increase or international prices rise, those dependencies can quickly become a problem for local manufacturers and ultimately for consumers.

Emzor’s planned investment is therefore aimed at addressing a much larger issue than the expansion of one company.

Why the antimalarial plant mattersOne of the major uses…